Amicoumacin A 

Amicoumacin A is an orally active antibiotic. Amicoumacin A targets bacterial ribosomes and inhibits bacterial translation by stabilizing the interaction between mRNA and ribosomes. Amicoumacin A induces cancer cell death by targeting eukaryotic ribosomes. Amicoumacin A exhibits anti-inflammatory and anti-ulcer activities, inhibits carrageenan-induced paw edema, and prevents stress-induced gastric ulcers. Amicoumacin A inhibits the growth of Gram-positive bacteria, Salmonella spp., Shigella spp., Helicobacter pylori, and methicillin-resistant Staphylococcus aureus. Amicoumacin A can be used in the research of lung cancer, breast cancer, bacterial infections, inflammatory edema and gastric ulcers^{[1][2][3][4][5]}.

Amicoumacin A (0-5 μM; 25-120 min) inhibits both scanning-dependent and IRES-dependent mRNA translation in HEK293T cells, Krebs-2 cell-free systems, and S. cerevisiae cell-free extracts^[1].
Amicoumacin A (100 μM; 5 min pre-incubation + 10 min mRNA incubation) inhibits mammalian translation elongation in rabbit reticulocyte lysates by stalling 80S ribosomes along mRNA^[1].
Amicoumacin A (50 nM-100 μM; 72 h) exhibits 2- to 4-fold greater cytotoxicity against human cancer cell lines (A549, MCF-7) than against non-cancerous cell lines (HEK293T, VA13), with IC₅₀ values ranging from 0.2 μM to 1.2 μM^[1].
Amicoumacin A (30 μM; 10 min) reduces the production level of tripeptides in E. coli ribosomes and impairs the ability of most ribosomes to complete multiple rounds of elongation cycles^[3].
Amicoumacin A (30 min at 37 °C) potently inhibits protein synthesis in E. coli S30 cell extracts with an IC₅₀ of 0.45 μM, and inhibits protein synthesis in the PURE system composed of purified translation components with an IC₅₀ of 0.20 μM^[4].
Amicoumacin A (0-1000 μM; 30 sec at 37 °C) inhibits ribosomal translocation in a concentration-dependent manner in vitro, with nearly complete inhibition observed at 1000 μM^[4].
Amicoumacin A (2 μM; 30 min at 37 °C) inhibits the synthesis of firefly luciferase in E. coli S30 cell extracts^[4].
Amicoumacin A exhibits inhibitory activity against Gram-positive bacteria^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Amicoumacin-A (10-50 mg/kg; p.o.; single dose) dose-dependently inhibits carrageenan-induced paw edema in male Wistar rats^[5].
Amicoumacin-A (10-25 mg/kg; p.o.; single dose) dose-dependently prevents stress-induced gastric ulcers in male Sprague-Dawley rats^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

423.46

C₂₀H₂₉N₃O₇

78654-44-1

O=C1C2=C(O)C=CC=C2C[C@@](O1)([H])[C@H](CC(C)C)NC([C@@H](O)[C@@H](O)[C@@H](N)CC(N)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Prokhorova IV, et al. Amicoumacin A induces cancer cell death by targeting the eukaryotic ribosome. Sci Rep. 2016;6:27720. Published 2016 Jun 14.  [Content Brief]

  [2]. Itoh, J., et al.. Isolation, Physicochemical Properties and Biological Activities of Amicoumacins Produced by Bacillus pumilus. Agricultural and Biological Chemistry, 46(5), 1255–1259.

  [3]. Maksimova EM, et al. Multifaceted Mechanism of Amicoumacin A Inhibition of Bacterial Translation. Front Microbiol. 2021;12:618857. Published 2021 Feb 12.  [Content Brief]

  [4]. Polikanov YS, et al. Amicoumacin a inhibits translation by stabilizing mRNA interaction with the ribosome. Mol Cell. 2014;56(4):531-540.  [Content Brief]

  [5]. Itoh J, et al. Amicoumacin-A, a new antibiotic with strong antiinflammatory and antiulcer activity. J Antibiot (Tokyo). 1981 May;34(5):611-3.  [Content Brief]